Pivotal Therapeutics, Inc.

Calculating rank

USPTO Granted Patents = 5

% Expired Patents = 20.0

Forward Citations = 3

Loading Chart...

5 inventors (with patents filed for the assignee):

George Jackowski (5 out of 71 patents)

Nisar Ahmad Shaikh (5 out of 5 patents)

Valerie B Schini-Kerth (5 out of 5 patents)

4. Rachelle MacSweeney (5 out of 5 patents)

5. Jason Yantha (5 out of 27 patents)

5 patents: Sort by Forward Citations

1. 9248138 - Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids (2016-02-02),

2. 9119826 - Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels (2015-09-01),

3. 8952000 - Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events (2015-02-10),

4. 8951514 - Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels (2015-02-10),

5. 8715648 - Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics (2014-05-06),

Company Overview

Pivotal Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for cardiovascular and metabolic diseases. Their flagship product, VASCAZEN, is a prescription medical food designed to manage certain lipid imbalances in patients with cardiovascular conditions. Pivotal Therapeutics is committed to improving patient outcomes and quality of life through their research and development efforts.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#330 in

#2,851 in Canada

CA